Polypeptide and application thereof in preparation of anti-rabies virus medicine

By designing the TAT-P58aRABV190 formed by the fusion of the polypeptide PDIA3 (190-199aa) with the cell penetrating peptide, the effective treatment problem of rabies virus infection was solved, and the significant inhibition and degradation of rabies virus was achieved, showing its antiviral field Potential application value.

CN119020340APending Publication Date: 2024-11-26WUHAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410904537.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-08
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Currently, there is a lack of effective treatments to save the lives of rabies patients. Traditional drugs have a poor prognosis for the disease, and there are no targeted polypeptide drugs for rabies viruses.

Method used

A polypeptide PDIA3 (190-199aa) and its polypeptide TAT-P58aRABV190 in fused form with cell penetrating peptide were designed to prepare anti-rabies virus drugs by binding to rabies virus surface glycoproteins to inhibit virus infection and replication.

Benefits of technology

The TAT-P58aRABV190 polypeptide significantly inhibits rabies virus infection, has good biocompatibility and safety, can promote the degradation of glycoprotein on the surface of the virus, inhibit early entry and replication cycles of the virus, and show potentially high-efficiency broad-spectrum antiviral activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020340A_ABST
    Figure CN119020340A_ABST
Patent Text Reader

Abstract

The invention discloses a polypeptide and application thereof in preparation of anti-rabies virus drugs, and belongs to the technical field of biological medicines. The amino acid sequence of the polypeptide is as shown in SEQ ID NO.1, the polypeptide is derived from 190-199 amino acids of human PDIA3 protein, the polypeptide can be fused with a cell penetrating peptide to form a polypeptide with an amino acid sequence as shown in SEQ ID NO.2, and the problems that the polypeptide is easy to degrade and difficult to enter cells are solved. The polypeptide can be combined with surface glycoprotein of the rabies virus to resist infection of the rabies virus, and can be used for preparing anti-rabies virus drugs. The polypeptide disclosed by the invention has the advantages of simple and feasible preparation method, good biocompatibility, small side effect, safety, high efficiency and the like, and can be produced on a large scale in a short time. The invention lays a foundation for designing safe and effective polypeptide for treating rabies, and has good development and application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a polypeptide and an application thereof in the preparation of an anti-rabies virus drug. Background Art

[0002] Rabies is a fatal zoonotic neurological disease caused by the rabies virus. Although rabies has been the focus of large-scale public health interventions, primarily through vaccination efforts, the disease causes an estimated 40,000 to 70,000 deaths worldwide each year [1]. Although the disease is less common than other human infections (such as influenza virus), there is a lack of effective treatment to save the lives of symptomatic rabies patients, and the prognosis after being bitten by a rabid animal is poor, with a mortality rate approaching 100% [2,3]. Human rabies remains one of the most serious diseases and a major threat to public health. Therefore, the search for effective anti-rabies drugs remains a difficult task at present, and further research is required in theory and practice.

[0003] In recent years, peptide drugs have become one of the research hotspots of targeted drugs due to their good biocompatibility, biodegradability and reactivity[4,5]. At present, peptide drugs synthesized by modern biotechnology have been widely used in the prevention, diagnosis and treatment of diseases such as tumors, hepatitis, diabetes, and AIDS[6]. Compared with traditional small molecule chemical drugs, protein drugs have good biological activity, strong specificity, low toxicity, clear biological functions, and are conducive to clinical application. They are often effective, have few adverse reactions, are highly safe, and rarely cause serious immune reactions[7]. Due to their own characteristics, the time required for peptides to go from clinical trials to FDA approval is also shorter than that of small molecule drugs, about 10 years on average. The probability of peptides passing clinical trials is twice as high as that of small molecule compounds. Currently, there are about 60 to 70 peptide drugs on the global drug market, such as somatuline, zoladex, sandostatin, secretin, leuprolide, ceruletide, bivalirudin, vasopressin, vapreotide, pramlintide, corticotropin, and bacitracin, etc. There are 200 to 300 peptide drugs in clinical trials, 500 to 600 in preclinical trials, and more peptide drugs in the laboratory research stage [8]. The specific advantages of peptides make them show specific advantages in drug development and have clinical application value. So far, there are no targeted peptide drugs for rabies virus.

[0004] References

[0005] [1] Dhulipala S and Uversky VN. Looking at the Pathogenesis of the Rabies Lyssavirus Strain Pasteur Vaccins through a Prism of the Disorder-Based Bioinformatics. Biomolecules[J], 2022, 12(10).

[0006] [2] Fooks AR, Cliquet F, Finke S, et al. Rabies. Nat Rev Dis Primers[J], 2017, 3:17091.

[0007] [3] Bastos V, Pacheco V, Rodrigues DL, et al. Neuroimmunology of rabies: New insights into an ancient disease. J Med Virol[J], 2023, 95(10):e29042.

[0008] [4] Mu R, Zhu D, Abdulmalik S, et al. Stimuli-responsive peptide assemblies: Design, self-assembly, modulation, and biomedical applications. Bioact Mater[J], 2024, 35:181 - 207.

[0009] [5] Guo XY, Yi L, Yang J, et al. Self-assembly of peptide nanomaterials at biointerfaces: molecular design and biomedical applications. Chem Commun(Camb)[J], 2024, 60(15):2009 - 2021.

[0010] [6]Wang M, Liu J, Xia M, et al. Peptide-drug conjugates: A new paradigm for targeted cancer therapy. Eur J Med Chem[J], 2024,265:116119.

[0011] [7]Ji

[0012] [8] de la Torre BG and Albericio F. The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules[J], 2024, 29(3). Summary of the invention

[0013] The purpose of the present invention is to provide a polypeptide capable of targeting rabies virus and its application in the preparation of anti-rabies virus drugs.

[0014] The purpose of the present invention is achieved through the following technical solutions:

[0015] A polypeptide PDIA3 (190-199aa) has an amino acid sequence of ESLVNEYDDN (SEQ ID NO. 1). PDIA3 (190-199aa) is derived from amino acids 190-199 of human PDIA3 protein, and can bind to the surface glycoprotein of rabies virus to resist rabies virus infection.

[0016] A polypeptide formed by fusing a cell-penetrating peptide and the above-mentioned PDIA3 (190-199aa) polypeptide. The PDIA3 (190-199aa) polypeptide has the problem of being easily degraded and difficult to enter cells to exert its effect. Fusion of the PDIA3 (190-199aa) polypeptide with the cell-penetrating peptide can solve this problem. The amino acid sequence of the cell-penetrating peptide is preferably YGRKKRRQRRR. When the amino acid sequence of the cell-penetrating peptide is YGRKKRRQRRR, the polypeptide is named TAT-P58aRABV190, and its amino acid sequence is YGRKKRRQRRRESLVNEYDDN (SEQ ID NO.2).

[0017] Furthermore, the above polypeptide is a C-terminal amidated polypeptide, which is artificially synthesized and has a purity of more than 95%.

[0018] The use of the above polypeptide PDIA3 (190-199aa) or a polypeptide formed by the fusion of a cell-penetrating peptide and PDIA3 (190-199aa) in the preparation of an anti-rabies virus drug. The drug resists rabies virus infection by at least the following actions: selectively degrading rabies virus surface glycoprotein, inhibiting the early entry of the virus into the host and the later stages of entering the host. The rabies virus includes the CVS11 strain.

[0019] An anti-rabies virus drug comprises the above-mentioned polypeptide PDIA3 (190-199aa) or a polypeptide formed by the fusion of a cell-penetrating peptide and PDIA3 (190-199aa), and may further comprise an auxiliary material component acceptable in pharmaceutical preparation.

[0020] The beneficial effects of the present invention are:

[0021] (1) Different concentrations of TAT-P58aRABV190 peptide did not affect cell activity and immune activation in HEK293 cells, and it was found that TAT-P58aRABV190 peptide had good biocompatibility with cells.

[0022] (2) The TAT-P58aRABV190 peptide significantly inhibited the infectivity of rabies virus in a dose-dependent manner, promoted the degradation of rabies virus surface glycoprotein, and inhibited the entry and post-entry stages of the replication cycle, indicating that the TAT-P58aRABV190 peptide has good antiviral activity and diverse antiviral mechanisms, and is a potential highly effective and broad-spectrum antiviral active peptide with important application value.

[0023] (3) TAT-P58aRABV190 peptide promotes the degradation of rabies virus surface glycoprotein and inhibits the early entry stage of rabies virus.

[0024] (4) TAT-P58aRABV190 peptide has the advantages of simple preparation method, good biocompatibility, small side effects, and can be mass-produced in a short period of time. As an antiviral drug, TAT-P58aRABV190 peptide is safe and efficient, laying the foundation for the design of safe and effective peptides for the treatment of rabies, and has good development and application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 :Different concentrations of TAT-P58aRABV190 peptide did not affect cell activity and immune activation in HEK293 cells. In the figure, ns: no significant difference.

[0026] 1A: amino acid sequence of TAT-P58aRABV190 polypeptide;

[0027] 1B: MTT assay to detect the effect of different concentrations of TAT-P58aRABV190 peptide on the activity of HEK293 cells;

[0028] 1C: qPCR detection of the effect of TAT-P58aRABV190 polypeptide on the mRNA levels of immune genes ifitm3 and ifit1 in HEK293 cells.

[0029] Figure 2 : TAT-P58aRABV190 polypeptide inhibits the infection of rabies virus CVS11 in HEK293 cells in a concentration-dependent manner. In the figure, **p<0.01, ***p<0.001.

[0030] 2A: Western blot detection of the inhibitory effect of TAT-P58aRABV190 peptide on the expression of G and M proteins of rabies virus CVS11;

[0031] 2B: qPCR detection of the inhibitory effect of TAT-P58aRABV190 polypeptide on the rabies virus CVS11 RNA content.

[0032] Figure 3 :TAT-P58aRABV190 peptide promotes the degradation of rabies virus surface glycoprotein and inhibits the early entry stage of rabies virus. In the figure, **p<0.01.

[0033] 3A: Western blot detection of the inhibitory effect of TAT-P58aRABV190 peptide on the expression of G protein of rabies virus CVS11;

[0034] 3B: Luciferase fluorescence immunoassay was used to detect the inhibitory effect of TAT-P58aRABV190 peptide on the entry of rabies virus CVS11 pseudovirus into cells.

[0035] Figure 4 :TAT-P58aRABV190 peptide can reduce the viral load in mice. In the figure, *p<0.05, **p<0.01, ***p<0.001. Scramble refers to a peptide composed of random amino acids (sequence: YGRKKRRQRRRFRLPSVHRFR).

[0036] 4A: Mouse body weight change curve.

[0037] 4B: qPCR detection of virus content in mouse brain. DETAILED DESCRIPTION

[0038] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not used to limit the scope of protection claimed in the present invention.

[0039] The TAT-P58aRABV190 polypeptide used in the following examples is a C-terminal amidated polypeptide, synthesized by a biological company with a purity of more than 95%, and its amino acid sequence is YGRKKRRQRRRESLVNEYDDN ( Figure 1 A).

[0040] The recombinant expression vector pQCXIP-G-Flag used in the following examples was constructed as follows: the empty pQCXIP-Flag (Fu, B., Wang, L., Li, S., and Dorf, ME (2017). ZMPSTE24 defends against influenza and other pathogenic viruses. J Exp Med 214, 919-929.) was digested with XhoΙ and NotΙ to obtain pQCXIP-Flag with XhoΙ and NotΙ restriction enzyme ports; the rabies virus surface glycoprotein G protein sequence was PCR-treated with the cDNA reverse transcribed from viral RNA as a template using the primer pair shown in SEQ ID NO.3-SEQ ID NO.4 to obtain the G gene fragment; the G gene fragment was then double-digested with XhoΙ and NotΙ and then ligated and transformed with the pQCXIP-Flag with XhoΙ and NotΙ restriction enzyme ports to obtain pQCXIP-G-Flag.

[0041] SEQ ID NO.3: TGACTCGAGGCCACCATGGTTCCTCAGGTTCTTT,

[0042] SEQ ID NO. 4: TATGCGGCCGCCAGTCTGATCTCACCTCC.

[0043] The recombinant CVS11 pseudovirus used in the following examples was obtained as follows:

[0044] (1) Construct a plasmid encoding the G protein of CVS11 on the pMD2.G vector (Addgene plasmid #12259; http: / / n2t.net / addgene:12259; RRID:Addgene_12259). Using the cDNA reverse transcribed from the viral RNA as a template, PCR was performed using the primer pair shown in SEQ ID NO.5-SEQ ID NO.6 to obtain the CVS11G gene fragment; using the pMD2.G vector as a template, PCR was performed using the primer pair shown in SEQ ID NO.7-SEQ ID NO.8 to obtain a linearized pMD2.G vector; then the G gene fragment was enzymatically ligated and transformed with the linearized pMD2.G vector using homologous recombinase to obtain pMD2.G-CVS11-G.

[0045] Primer name Sequence (5'-3') SEQ ID.5 GAGATCTGAATTCTGACACTATGGTTCCTCAGGTTCTT SEQ ID.6 TCTGTTGTGCAGGATTTGAGCAGTCTGATCTCACCTCCA SEQ ID.7 GAGATCTGAATTCTGACAC SEQ ID.8 TCTGTTGTGCAGGATTTGAG

[0046] (2) The luciferase reporter gene was constructed into the FUGW vector (Lois, C., Hong, EJ, Pease, S., Brown, EJ, and Baltimore, D. (2002). Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295, 868-872.). The plasmid carrying the luciferase gene sequence was used as a template and the primer pair shown in SEQ ID NO.9-SEQ ID NO.10 was used to perform PCR to obtain the luciferase reporter gene luciferase gene fragment; the FUGW vector was used as a template and the primer pair shown in SEQ ID NO.11-SEQ ID NO.12 was used to perform PCR to obtain the linearized FUGW vector; then the luciferase gene fragment was enzymatically linked and transformed with the linearized FUGW vector using homologous recombinase to obtain FUGW-luciferase.

[0047] Primer name Sequence (5'-3') SEQ ID.9 CCGGGTACCGGTCGCCACCATGGAAGACGCCAAAAAC SEQ ID.10 TATCGATAAGCTTGATATCGTTACAATTTGGACTTTCC SEQ ID.11 CGATATCAAGCTTATCGATA SEQ ID.12 GGTGGCGACCGGTACCCGG

[0048] (3) A second-generation lentiviral packaging system was used, including a packaging plasmid (psPAX2), an envelope plasmid (pMD2-G), and a target gene plasmid (FUGW-luciferase). HEK293T cells were plated in 6-well plates, with 3×10 cells per well. 6The next day, OPTI-MEM reduced serum medium (Gibco, 51985034) and Lipofectamine TM Three plasmids psPAX2 (750 ng / well), pMD2-G (250 ng / well) and FUGW-luciferase (1000 ng / well) were co-transfected with 2000 transfection reagent (Invitrogen, 1679991). The cells were incubated at 37°C and 5% CO 2 The cells were cultured under the same conditions for 6 hours, and then the culture medium containing 10% fetal bovine serum was replaced and cultured continuously. After 72 hours, the transfection supernatant was collected and clarified by centrifugation at 300×g for 10 minutes to obtain a pseudovirus suspension containing the luciferase reporter gene CVS11. The titer of each virus stock solution was determined and stored at -80°C after aliquoting.

[0049] Example 1 Effects of TAT-P58aRABV190 polypeptide on MTT toxicity test results and immune activation

[0050] (1) HEK293 cells were seeded in a 96-well plate at a cell concentration of 1×10 per well. 4 , cultured overnight.

[0051] (2) The next day, aspirate the cell supernatant and wash the cells three times with PBS solution.

[0052] (3) Culture medium containing different concentrations of TAT-P58aRABV190 polypeptide (drug concentrations were: 0, 0.01, 0.1, 1, and 10 μg / mL) was added to each well of the experimental group cells and cultured for 24 and 36 hours, respectively.

[0053] (4) After reaching the pre-designed time point, remove the drug-containing medium, wash the cells three times with PBS solution, and add 100 μL of MTT solution (0.5 mg / mL) to each well.

[0054] (5) After 4 hours of continuous culture, the culture medium was removed and 200 μL of DMSO solution was added to each well. The plate was placed in a shaker and shaken at a low speed of 150 rpm for 15 minutes to completely dissolve the generated purple crystals.

[0055] (6) The optical density (OD) value of each well was measured using a multifunctional microplate reader. Untreated cells were used as negative controls, and cells treated with 1% Triton X-100 solution (v / v) were used as positive controls. Five biological parallels were set up for each group.

[0056] MTT test results Figure 1 As shown in Figure B, it can be seen from the figure that the TAT-P58aRABV190 polypeptide has no obvious toxic side effects on HEK293 cells.

[0057] HEK293 cells were treated with the same concentration gradient of TAT-P58aRABV190 peptide for 6 hours, and the mRNA levels of the immune genes ifitm3 and ifit1 of the cells were detected by qPCR experiments. Figure 1 As shown in C, TAT-P58aRABV190 polypeptide has no obvious activation effect on HEK293 cell immunity.

[0058] qPCR primers: ifitm3 upstream primer: 5'-CTGGGCTTCATAGCATTCGCCT-3', downstream primer: 5'-AGATGTTCAGGCACTTGGCGGT-3'; ifit1 upstream primer: 5'-GCCTTGCTGAAGTGTGGAGGAA-3', downstream primer: 5'-ATCCAGGCGATAGGCAGAGATC-3'.

[0059] Example 2 Antiviral Experimental Results of TAT-P58aRABV190 Peptide

[0060] (1) HEK293 cells were seeded in a 24-well plate at a cell concentration of 1×10 5 , cultured overnight.

[0061] (2) The next day, aspirate the cell supernatant and wash the cells three times with PBS solution.

[0062] (3) Prepare virus suspension: 120 μL rabies virus CVS-11 suspension (concentration 1×10 5 FFU / mL) was added to 10 ml of DMEM. The prepared virus suspension was then added to a 24-well plate, 400 μL per well, and cultured in an incubator for 2 hours.

[0063] (4) After culturing to a set time point, TAT-P58aRABV190 polypeptide was added to the well plate to achieve different final concentration gradients: 0, 0.01, 0.1, 1, and 10 μg / mL.

[0064] (5) After continuing to culture for 48 hours, the drug-containing medium was removed, and the cells were washed three times with PBS solution. 100 μL of RIPA lysis buffer (Biyuntian Biotechnology Company, P0013B) was added to each well.

[0065] (6) After cell lysis, the cells were centrifuged at 15,000 rpm for 10 minutes, the supernatant was collected, and the expression levels of rabies virus (RV) CVS11 G protein and M protein were detected by western blot.

[0066] Test results such as Figure 2As shown in A, it can be seen from the figure that the TAT-P58aRABV190 polypeptide inhibits the infection of rabies virus in a dose-dependent manner, among which 0.01 μg / mL significantly inhibits the infection of rabies virus, indicating that the TAT-P58aRABV190 polypeptide has the effect of resisting rabies virus.

[0067] Similarly, the rabies virus CVS-11 RNA content in the cells treated with steps (1)-(4) for 24 hours was detected by qPCR. The results are as follows Figure 2 As shown in B, TAT-P58aRABV190 polypeptide 1 and 10 μg / mL can significantly inhibit the viral RNA content in cells. These results indicate that TAT-P58aRABV190 polypeptide can effectively inhibit rabies virus infection.

[0068] qPCR primers: CVS11 upstream primer: 5′-GTTTCAGTGACCAACGGTGC-3′, downstream primer: 5′-GCTTAGATGACCCAGCCCTC-3′.

[0069] Example 3 TAT-P58aRABV190 polypeptide promotes the degradation of rabies virus surface glycoprotein

[0070] (1) HEK293 cells were seeded in a 24-well plate at a cell concentration of 1×10 5 , cultured overnight.

[0071] (2) The next day, HEK293 cells were transfected with the pQCXIP-G-Flag vector using lipo2000 and cultured for another 24 hours.

[0072] (3) After culturing to a set time point, TAT-P58aRABV190 polypeptide was added to the well plate to a final concentration of 10 μg / mL.

[0073] (4) After culturing for 16 hours, the drug-containing medium was removed and the cells were washed three times with PBS solution. 100 μL of RIPA lysis buffer (Biyuntian Biotechnology Company, P0013B) was added to each well.

[0074] (5) After cell lysis, the cells were centrifuged at 15,000 rpm for 10 min, the supernatant was collected, and analyzed by western blot.

[0075] Test results such as Figure 3 As shown in A, it can be seen from the figure that treatment with 10 μg / mL TAT-P58aRABV190 polypeptide can significantly inhibit the level of exogenously expressed CVS11 surface glycoprotein, indicating that TAT-P58aRABV190 polypeptide can inhibit rabies virus infection by promoting the degradation of CVS11 surface glycoprotein.

[0076] Example 4 TAT-P58aRABV190 polypeptide inhibits rabies virus CVS11 pseudovirus from entering cells

[0077] (1) HEK293 cells were seeded in a 24-well plate at a cell concentration of 1×10 5 , cultured overnight.

[0078] (2) The next day, aspirate the cell supernatant and wash the cells three times with PBS solution.

[0079] (3) Prepare virus suspension: 240 μL of CVS11 pseudovirus suspension carrying the luciferase reporter gene and containing only rabies virus surface glycoprotein G (2 × 10 6 TU / mL) was added to 10 ml of DMEM. The prepared virus suspension was then added to a 24-well plate, 400 μL per well, and cultured in an incubator for 36 hours.

[0080] (4) After culturing to a set time point, TAT-P58aRABV190 polypeptide was added to the well plate to achieve different final concentration gradients: 0, 0.01, 0.1, 1, and 10 μg / mL.

[0081] (5) After continuing to culture for 48 hours, the drug-containing medium was removed, and the cells were washed three times with PBS solution. 100 μL of RIPA lysis buffer (Biyuntian Biotechnology Company, P0013B) was added to each well.

[0082] (6) After cell lysis, centrifuge at 15,000 rpm for 10 minutes and collect the supernatant for testing.

[0083] (7) Detect the luciferase activity in the supernatant of the lysate using a multifunctional microplate reader.

[0084] Test results such as Figure 3 As shown in Figure B, it can be seen from the figure that treatment with TAT-P58aRABV190 polypeptide can significantly inhibit the entry of rabies virus pseudovirus into cells, indicating that TAT-P58aRABV190 polypeptide can inhibit the infection of rabies virus by inhibiting the early entry of rabies virus into cells.

[0085] Example 5 TAT-P58aRABV190 polypeptide rescues weight loss in mice infected with rabies virus

[0086] (1) Female C57BL / 6J mice aged 6-8 weeks were weighed and anesthetized with 2.5% tribromoethanol;

[0087] (2) Mice were infected with RABV CVS11 strain (100 FFU / mL) via intranasal drip;

[0088] (3) Two hours later, the mice were intraperitoneally injected with TAT-P58aRABV190 polypeptide at a dose of 0.5 mg / kg body weight, and the body weight of the mice was then observed and recorded every 24 hours.

[0089] Test results such as Figure 4 As shown in A, it can be seen from the figure that compared with the control group using scramble peptide, treatment with TAT-P58aRABV190 peptide can rescue the weight loss of mice caused by rabies virus infection, indicating that TAT-P58aRABV190 peptide can inhibit rabies virus infection in mice. Scramble refers to a polypeptide composed of random amino acids (sequence: YGRKKRRQRRRFRLPSVHRFR).

[0090] Example 6 TAT-P58aRABV190 polypeptide reduces rabies virus content in mouse brain

[0091] (1) Female C57BL / 6J mice aged 6-8 weeks were weighed and anesthetized with 2.5% tribromoethanol;

[0092] (2) Mice were infected with the RABVCVS11 strain (100 FFU / mL) via intranasal drip;

[0093] (3) 2 hours later, TAT-P58aRABV190 peptide was injected intraperitoneally at a dose of 0.5 mg / kg body weight;

[0094] (4) After 5 days, the mice were killed and their brain tissues were removed. The homogenized and broken tissues were used for qPCR experiments to detect the viral content. qPCR primers: CVS11 upstream primer: 5'-GTTTCAGTGACCAACGGTGC-3', downstream primer: 5'-GCTTAGATGACCCAGCCCTC-3'.

[0095] Test results such as Figure 4 As shown in Figure B, it can be seen that treatment with TAT-P58aRABV190 polypeptide reduces the rabies virus content in the mouse brain, indicating that TAT-P58aRABV190 polypeptide can inhibit rabies virus infection in mice.

[0096] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present invention.

Claims

1. A polypeptide, Features: The amino acid sequence is ESLVNEYDDN.

2. A polypeptide formed by fusion of a cell penetrating peptide and the polypeptide according to claim 1.

3. The polypeptide according to claim 2, Features: The amino acid sequence of the cell penetrating peptide is YGRKKRRQRRR.

4. The polypeptide according to claim 3, Features: The amino acid sequence is YGRKKRRQRRRESLVNEYDDN.

5. A polypeptide, Features: Containing the polypeptide according to any one of claims 1 to 4.

6. The polypeptide according to any one of claims 1 to 5, Features: It is a C-terminally amidated peptide.

7. Use of the polypeptide according to any one of claims 1 to 6 in the preparation of anti-rabies virus drugs. 8.An anti-rabies virus drug, Features: Comprising the polypeptide according to any one of claims 1 to 6.

9. The drug according to claim 8, Features: It also contains excipient ingredients that are acceptable in pharmaceuticals.

10. The use according to claim 7 or the medicine according to claim 8 or 9, Features: The drug resists rabies virus infection by at least the following actions: selectively degrading rabies virus surface glycoprotein, inhibiting the early stage of virus entry into the host and the later stage of entry into the host.